Marmon Plumbing & Refrigeration has completed live, aerosolized COVID-19 testing on Marmon’s new CerroZone continuous indoor air purification system at the University of Missouri Laboratory for Infectious Disease Research (LIDR).
Early indications show the device has recorded more than 99 percent reduction of live COVID-19 in a single pass in under 30 seconds. Confirmation of the efficacy data by the University of Missouri’s LIDR team, led by Dr. Jeffrey Adamovicz, is expected.
CerroZone recorded a 99.999957 percent (6.57 LoG) particulate reduction on the FDA proxy virus for SARS-CoV-2 (RNA virus MS2) at ARE Labs in Olathe, Kan.
The patent-pending system was developed in conjunction with Micron Pure, a Hecto Group company.
“We are excited and proud to introduce the CerroZone™ suite of products in the battle against COVID-19,” says Michael Duggan, vice president of Innovation for Marmon Plumbing & Refrigeration. “CerroZone offers proven performance in an accredited laboratory using live, airborne COVID-19. This sets us apart and provides the market a compelling opportunity in every respect.”
Duggan said CerroZone also will be tested on other pathogens, such as MRSA and influenza.
He adds: “As CerroZone™ is selected and installed, buildings will be able to display information about the benefits of our technology, thus providing the public with an important measure of confidence about air quality as they seek to safely return to workplaces, schools, medical centers, restaurants, entertainment venues, hotels and other sites.”
Marmon will apply under Section 510(k) of the Food, Drug and Cosmetic Act, which requires device manufacturers to notify the FDA of their intent to market a medical device at least 90 days before launching the product.